UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): May 13, 2005
The Medicines Company
(Exact Name of Registrant as Specified in Charter)
Delaware | | 000-31191 | | 04-3324394 |
(State or Other Jurisdiction
of Incorporation) | | (Commission
File Number) | | (IRS Employer
Identification No.) |
| | | | |
8 Campus Drive
Parsippany, New Jersey | | 07054 |
(Address of Principal Executive Offices) | | (Zip Code) |
Registrant’s telephone number, including area code: (973) 656-1616
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.01. Entry into a Material Definitive Agreement
On May 13, 2005, the Compensation Committee of the Board of Directors of The Medicines Company (the “Company”) approved the annual base salaries for each of the Company’s executive officers effective as of January 1, 2005 and May 2, 2005, respectively, as set forth in the table below:
| | 2005 Annual Salary | |
| | Effective as of
January 1, 2005 | | Effective as of
May 2, 2005 | |
Clive A. Meanwell | | $ | 425,000 | | $ | 425,000 | |
John P. Kelley | | $ | 315,000 | | $ | 315,000 | |
Steven H. Koehler | | $ | 292,188 | | $ | 295,625 | |
John D. Richards | | $ | 187,850 | | $ | 203,320 | |
Paul M. Antinori | | $ | 207,188 | | $ | 234,000 | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| THE MEDICINES COMPANY |
| |
| | |
Date: May 19, 2005 | By: | /s/ Steven H. Koehler | |
| | Steven H. Koehler |
| | Senior Vice President and Chief Financial Officer |
2
